	Total Estimated				
	Contract Number	Amount Obligated	Contract Value	Vendor Name	Description of Requirement
					Influence of raw materials, manufacturing variables, and
					storage conditions on release performance of long-acting
1	HHSF223201810187C	\$324,410.00	\$1,482,306.00	Regents of the University of Michigan	release microsphere products
					Identification and Assessment of Patient-Reported Outcome
2	HHSF223201810189C	\$106,664.00	\$106,664.00	American Society of Nephrology, Inc.	Measures (PROMs) for Novel Renal Devices
					Physiologically-based model of the female reproductive tract:
				The Research Foundation for the State	vaginal and intrauterine delivery components – Support New
3	HHSF223201810188C	\$458,014.00	\$888,097.00	Univeristy of New York	Approaches to Improve Product Manufacturing and Quality
					Comprehensive Spatio-Temporal Map of Gene Expression
4	HHSF223201810172C	\$942,075.00	\$2,283,839.00	The Broad Institute, Inc.	During Lethal Ebola Virus Disease
		4.00.00	*		Develop Data Analysis Techniques and Perform Data Profiling
5	HHSF223201810123C	\$406,408.00	\$406,408.00	EDJ Analytics, LLC	in Order to Improve Overall Regulatory Data Quality
					Immunogenicity Risk of Peptide Drug Generics and their
	11115522222040404066	¢500.076.20	64 072 220 42	CURROLL	Impurities: In Silico and In Vitro Assessment and Validation
6	HHSF223201810186C	\$500,076.20	\$1,072,328.42	CUBRC, Inc.	Methods
7	HHSF223201810182C	\$159,903.00	\$400.761.00	CFD Research Corporation	A Multiscale Computational Framework for Bioequivalence of Orally Inhaled Drugs
	11113F223201610162C	\$159,505.00	\$455,701.00	CFD Research Corporation	Training Decay Selection for Medical Product Usability
8	HHSF223201810158C	\$401,691.88	\$401 691 88	UserWise, Inc.	Validation Testing
	111312232010101300	ψ 101/031.00	Ţ 101,031.00	oser wise, inc.	Confidence in Decision-Making: Evaluating a Structured
					Reporting Template to Increase Transparency and reduce
9	HHSF223201810136C	\$120,000.00	\$120,000.00	Brigham and Womens Hospital, Inc	Review Time for Healthcare Database Studies
		. ,	. ,	,	Developing novel kidney transplant drug development tools
					to enhance regulatory decision making and enable innovation
10	HHSF223201810184C	\$569,688.00	\$2,590,422.00	The Critical Path Institute	in medical product development
					Holistic Approach for Potential Drug Interactions with
					Botanical Drugs - importance of Chemical Fingerprinting and
11	HHSF223201810175C	\$1,454,560.00	\$1,454,560.00	University of Mississippi	Bio-Similarity
					Effects of Medical Products on Suicidal Ideation and Behavior
12	HHSF223201810201C	\$5,733,684.00		Kaiser Foundation Hospitals	– Real World Evidence
13	HHSF223201810326P	\$247,954.00	\$949,307.00	Conceptant, Inc.	Visualizing Interconnected Projects
				Sharp Mary Birch Hospital For Women	Conduct a study entitled, "Manganese Contamination in
	HHSF223201810150C	\$30,404.00		and Newborns	Neonatal Parenteral Nutrition.
15	HHSF223201810208C	\$249,000.00	\$249,000.00	WebMD Health Corp.	Lupus clinical research participation study
					Understanding of Safe Medication Use By Women's Health
16	HHSF223201810148C	\$218,000.00	\$218,000.00	WebMD Health Corp.	Special Populations

			Total Estimated		
	Contract Number	Amount Obligated	Contract Value	Vendor Name	Description of Requirement
					Effectiveness research with Real World Data to support FDA's
					regulatory decision making: A Real World Evidence
17	HHSF223201810146C	\$1,604,165.00	\$1,604,165.00	Brigham and Womens Hospital, Inc	Demonstration Project
					An Integrated Multiscale-Multiphysics Framework for
18	HHSF223201810151C	\$159,922.00	\$159,922.00	CFD Research Corporation	Evaluation of Generic Ophthalmic Drug Products
					Evaluating Batch to Batch Variability and its Origins in Dry
19	HHSF223201810169C	\$374,884.00	\$374,884.00	University of Texas at Austin	Powder Inhalers
					Patient Preference Information: Bridging Regulatory Decisions
20	HHSF223201810163C	\$699,201.00		Duke University	and Clinical Practice
21	HHSF223201810044C	\$289,719.00	\$289,719.00	AntiCoagulation Forum Inc.	Core Elements of Anticoagulation Stewardship
					21st Century Cures - DEVELOPMENT, ASSESSMENT AND VALIDITY COMPARISON OF APPROACHES TO ELICITING
					PATIENT PREFERENCES ACROSS RISK GROUPS: A CASE STUDY
					ON INNOVATIVE PREFERENCE SENSITIVE TREATMENTS (TYPE
				The Regents of the University of	1 DIABETES OR HEREDITARY RETINAL DYSTROPHY OR
22	HHSF223201810128C	\$192,364.00	\$192,364.00	California, San Francisco	OSTEOARTHRITIS)
					Center for Biologics Evaluation and Research's (CBER) Patient
23	HHSF223201810129C	\$364,781.00	\$364,781.00	Research Triangle Institute	Preference Study
					In Vitro and In Vivo Assessment of Ophthalmic Ointments for
24	HHSF223201810114C	\$385,768.00	\$1,141,038.00	University of Connecticut	Generic Product Equivalence
					Formative Research Study to Understand the Impact of
					Generic Drug-Device Substitutes for Various Patient and
25	HHSF223201810113C	\$118,578.00	\$277,849.00	Research Triangle Institute	Caregiver Populations
			4	Trustees of the University of	A scalable, patient-centered approach for "right sizing" opioid
26	HHSF223201810209C	\$651,762.00	\$1,122,452.00	Pennsylvania	prescribing study
			4		Impact of Polymer Source Variations on Parenteral
27	HHSF223201810115C	\$245,419.00	\$245,419.00	University of Connecticut	Microsphere Drug Product Performance
					Toxicity and Carcinogenicity Profiling of Tobacco Products via
28	HHSF223201810127C	\$1,408,195.00	\$3,445,344,00	Regent of the University of Colorado	Organ Microengineering and Systems Biology
		7-7:33/200100	72,112,211100	-5	Safety of Gadolinium-Enhanced MRI Exposure During
29	HHSF223201810083C	\$329,475.00	\$329,475.00	University of Florida	Pregnancy on Adverse Fetal Outcomes
		. ,	· ·	•	Regulatory Decision Making through the Use of High Quality
30	HHSF223201810084C	\$1,992,737.48	\$1,992,737.48	Deloitte Consulting, LLP	and Standardized Data
					Framework for Incorporating Patient Input into Medical
31	HHSF223201810116C	\$880,000.00		Medical Device Innovation Consortium	Device Clinical Trials
32	HHSF223201810082C	\$228,760.00	\$228,760.00	National Academy of Sciences	Updating Labels for Generic Oncology Drugs
					Healthy Citizen - Enhancing Public Health Through Citizen-
33	HHSF223201810077C	\$499,483.99	\$499,483.99	Conceptant, Inc.	Centric Communications

	Contract Number	Amount Obligated	Total Estimated Contract Value	Vendor Name	Description of Requirement
		-			Identification and Validation of a Biomarker of Electronic
34	HHSF223201810194C	\$896,696.00	\$896,696.00	Research Triangle Institute	Cigarette Exposure
					Evaluating Relationships Between In Vitro Nasal
					Spray Characterization Test Metrics for Bioequivalence and
				Virginia Commonwealth University	Nasal Deposition In
35	HHSF223201810144C	\$521,920.00	\$521,920.00	(VCU)	Silico and In Vitro
					Better Understanding Risk Mitigation in the Evaluation of
36	HHSF223201810112C	\$254,902.00	\$254,902.00	University of Birmingham UK	Relative Bioavailability of Pediatric Generic Products
				ANN & ROBERT H. LURIE CHILDREN'S	Comparative Safety of Complex Feeding Device Types among
37	HHSF223201810051C	\$70,473.00	\$139,502.00	HOSPITAL	NICU graduates
					Methodological Advances In Evaluating Abuse Deterrent
38	HHSF223201810183C	\$3,205,422.00	\$6,584,713.00	University of North Carolina	Opioid Analgesics
					Development of a Mouse Model for Preclinical Screening of
					Investigational Drugs Against Pseudomonas Aeruginosa and
39	HHSF223201810171C	\$933,606.00	\$986,328.00	University of Louisville	Acinetobacter Baumannii

\$28,230,765.55 \$41,786,669.77